among other prognostic factors. Median follow-up was 31 months for patients 65 years and 16 months for patients >65 years (Fig2). Conclusion: Daily low-dose cisplatin and high dose radiotherapy in stage III NSCLC is as tolerable for both young and older patients resulting in similar toxicity and overall survival.
Background: After pulmonary resections, one or two chest tubes are used, and the choice is based mainly on local habits rather than on evidence. The aim of the study was to evaluate the impact of quantitatively assessed emphysema on chest drainage using one or two tubes in patients with non-small cell lung cancer (NSCLC). Method: Single-centre, prospective randomized trial including patients who underwent lobectomy for NSCLC between February 2016 and December 2017. At the end of the operation, patients were randomized in a 1:1 ratio to the single tube group or to the two tubes group. On the day of surgery, controlled suction of -20 cm H2O was used, switched on the 1st postoperative day to -8 cm H2O. Amount and duration of air leak, chest tube output and differential pleural pressure were recorded using digital chest drainage system. Prolonged air leak was defined as leak lasting >72 h. Chest tubes were removed in the absence of air leak for more than 24 hours, and the chest tube output <250 mL/day. Quantitative analysis of emphysema was performed using the syngo CT. 3D Pulmo software. Result: There were 160 patients enrolled, including 100 men, mean age 65.15 years (range: 32-83) and 60 women, mean age 64.58 years (range: 24-81). One chest tube was used in 82 patients, including 52 cases of VATS lobectomy and 108 cases of open lobectomy. Two chest tubes were used in 78 patients, including 22 patients after VATS lobectomy and 56 after open lobectomy. Quantitative assessment of emphysema was performed in a CT study in 160 patients via an assessment evaluation index. In the single chest tube group there was significantly less air leak in first six hours (124.26 vs. 257.1mL/ min; p ¼ 0.01),volume of chest tube output (241.08 vs 345.82 mL; p ¼ 0.000015), and differential in first six hours pleural pressure (2.55 vs 3.14 cm H20); p ¼ 0.041. Multivariate regression analysis has shown significant effect of lung volume (dV) (p ¼ 0.007) and mean lung density (dMLD) (p ¼ 0.012) for prolonged air leak in the single chest tube group. In two chest tube group, a significant impact of lung volume (p ¼ 0.002) on the volume of chest tube output was found. Conclusion: Emphysema and lung volume affect the prolonged air leak following lung resection. Keywords: Lung cancer, digital chest drainage system, chest tube, air leak, pulmonary lobectomy, syngo CT. Pu
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Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression X. Gong, 1 X. Li, 2 Y. Xu, 3 C. Zhou 3 1 Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/CN, 2 Tongji University Cancer Institute, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/CN, 3 Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/CN Background: Lung cancer is a highly immune-suppressing malignancy with numerous methods to evade antitumor immune responses, including deficiencies in antigen processing and presentation, release of immunomodulatory cytokines, and inhibition of T cell activation. Our previous research also demonstrate that radiation can induce a local inflammatory response and simultaneously induce programmed death ligand 1 (PD-L1) expression that attenuate the sensitivity of radiation response in NSCLC. Current data have implicated that the molecular mechanisms by which DHA functions as radiosensitizer are varied, such as inducing apoptosis, extracellular signal-regulated protein kinases 1/2 (Erk1/2) activity, nuclear factor-kappa-B (NF-ƘB), and so on. However, there is no research about the immunity system alterations after the treatment of DHA plus radiation.In the present study, we demonstrate that combined DHA and radiotherapy synergistically enhances the anti-tumor effect by inhibiting the expression of PD-L1, eradicating the local accumulation of tumorinfiltrating regulatory T cells (iTregs) and myeloid-derived suppressor cells (MDSCs) and stimulating CD8+ T cell infiltration in the tumor microenvironment. Furthermore, DHA may also through inhibiting TGF-b, p-AKT and p-STAT3 pathways, epithelial-mesenchymal transition (EMT) process, facilitating apoptosis, and regulating TRIM21 to induce the synergistic anti-tumor effect. Method: Radiation resistance cell lines (A549/X) was induced from A549 by conventionally fractionated radiation. The relationship between PD-L1 expression and the radiation resistance and the immune cell was investigated by immunohistochemistry (IHC) and western blot in vitro and vivo. Apoptosis was evaluated by flow cytometry. The signaling pathway proteins, epithelial-mesenchymal transition (EMT)-related protein were analyzed by western blot. Result: PD-L1 was up-regulated after radiation in vivo and vitro. Concomitant with radiation-mediated tumor regression, combined DHA and radiotherapy synergistically enhances the anti-tumor effect by inhibiting the expression of PD-L1. DHA plus radiotherapy also reduced the local accumulation of tumor-infiltrating regulatory T cells (iTregs) and myeloid-derived suppressor cells (MDSCs) and stimulated CD8+ T cell infiltration in the tumor microenvironment. Furthermore, DHA may also through inhibiting TGF-b, p-AKT and p-STAT3 pathways, epithelial-mesenchymal transition (EMT) process, facilitating apoptosis, and regulating TRIM21 to induce the synergistic anti-tumor effect. Conclusion: Our study demonstrated a synergistic antitumor effect of DHA in combination with radiation trough abrogating immunity escaping via inhibiting PD-L1 expression, which establish a basis for the rational design of combination therapy of DHA plus radiotherapy in NSCLC. Background: The efficacy of platinum-based adjuvant chemotherapy(PBAC) varies for stage II-IIIA resected lung adenocarcinoma(RLUAD) patients, which necessitates the discovery of new potentially prognostic biomarkers. As a major source of genomic variations driving tumor evolution, somatic copy number alterations(CNAs) screening may identify predictive biomarkers. Method: The patterns of CNAs were analyzed by Oncoscan MIP array on formalin fixed paraffin embedded(FFPE) tumor specimens collected from 163 consecutive stage II-IIIA RLUAD patients, 145 out of which received PBAC. Result: Among the 163 patients, 91(55.8%) relapsed within three years after surgery. The most frequent aberrations identified were 1q, 5p, 5q, 7p, 8q, 14p, 16p, 17q, 20q for copy number gains and 8p, 9p, 13p, 16q , 18q for losses. GISTIC2 analysis generated 45 amplification peaks and 40 deletion peaks, including some significantly mutated genes TERT, EGFR, MYC, CCND1, CDK4, MDM2, ERBB2, NKX2-1, CCNE1, CDKN2A, most of which were consistent with TCGA database. It was found that amplifications of 12p12.1 (CMAS, GOLT1B, GYS2, LDHB, RECQL, ETNK1, IAPP, PYROXD1, KRAS) and KDM5A were associated with worse prognosis in our cohort(table), and validated in 506 LUADs from TCGA. 163 patients could be well classified into 4 groups with significantly different clinical outcomes based on thresholded copy number at reoccurring alteration peaks from GISTIC2 analysis. Among the 145 received PBAC patients, focal amplification of ERBB2 and deletion of 4q34.3 were found to be specific in relapsed patients compared with unrelapsed patients,This result was validated in an independent 183 cases corhort in Imielinski et al, indicating these two CNAs may contribute to RLUAD recurrence. Conclusion: This study suggests that CNAs may be a potential prognostic classifier in RLAUD patients, amplifications of 12p12.1 and KDM5A might be prognostic biomarkers for RLUAD , and amplification of ERBB2 and deletion of 4q34.3 predicted early relapse after PBAC. These novel findings may provide implication for better clinical decision making. Keywords: FFPE, lung adenocarcinoma, copy number alterations
